[go: up one dir, main page]

PE20081475A1 - Arilamidas sustituidas por tiazol u oxazol - Google Patents

Arilamidas sustituidas por tiazol u oxazol

Info

Publication number
PE20081475A1
PE20081475A1 PE2007001531A PE2007001531A PE20081475A1 PE 20081475 A1 PE20081475 A1 PE 20081475A1 PE 2007001531 A PE2007001531 A PE 2007001531A PE 2007001531 A PE2007001531 A PE 2007001531A PE 20081475 A1 PE20081475 A1 PE 20081475A1
Authority
PE
Peru
Prior art keywords
alkyl
methyl
straight
thiazol
substituted
Prior art date
Application number
PE2007001531A
Other languages
English (en)
Inventor
Li Chen
Michael Patrick Dillon
Lichun Feng
Ronald Charles Hawley
Minmin Yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20081475A1 publication Critical patent/PE20081475A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A COMPUESTOS ARILAMIDAS SUSTITUIDAS DE FORMULA (I), EN DONDE R1 ES UN GRUPO DE FORMULA A) O B), EN DONDE X ES S u O; Ra Y Rb SON INDEPENDIENTEMENTE H, ALQUILO(C1-C6), ALQUILO(C1-C6)-SULFONIL-ALQUILO(C1-C6), ENTRE OTROS; O JUNTOS AL ATOMO QUE ESTAN UNIDOS FORMAN FENILO OPCIONALMENTE SUSTITUIDO; R2 ES FENILO, PIRIDINILO, PIRIMIDINILO, ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS; R3 ES H, ALQUILO(C1-C6), HETERO-ALQUILO(C1-C6) O CIANO; R4 ES H, ALQUILO(C1-C6) O HETERO-ALQUILO(C1-C6); R5 ES ALQUILO(C1-C6), HETERO-ALQUILO(C1-C6), HALO-ALQUILO(C1-C6), ENTRE OTROS; R8 ES H, ALQUILO(C1-C6), HETERO-ALQUILO(C1-C6), ENTRE OTROS. SON SELECCIONADOS [2-(4-METANOSULFONIL-PIPERAZIN-1-IL)-1-METIL-ETIL-AMIDA DEL ACIDO 2'-FLUOR-4'-METIL-5-TIAZOL-5-IL-BIFENIL-3-CARBOXILICO, (2-METOXI-1-METIL-ETIL)-AMIDA DEL ACIDO 4'-METIL-5-OXAZOL5-IL-BIFENIL-3-CARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON ANTAGONISTAS DE LOS RECEPTORES PURINERGICOS P2X Y EN PARTICULAR DE P2X3 Y/O P2X2/3; SIENDO UTILES EN EL TRATAMIENTO DEL DOLOR, DE TRASTORNOS GENITO URINARIOS, GASTROINTESTINALES Y RESPIRATORIOS
PE2007001531A 2006-11-09 2007-11-07 Arilamidas sustituidas por tiazol u oxazol PE20081475A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85828306P 2006-11-09 2006-11-09

Publications (1)

Publication Number Publication Date
PE20081475A1 true PE20081475A1 (es) 2008-10-18

Family

ID=39149180

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001531A PE20081475A1 (es) 2006-11-09 2007-11-07 Arilamidas sustituidas por tiazol u oxazol

Country Status (17)

Country Link
US (1) US7786110B2 (es)
EP (1) EP2091927B1 (es)
JP (1) JP5084839B2 (es)
KR (2) KR101152714B1 (es)
CN (1) CN101528717B (es)
AR (1) AR063601A1 (es)
AT (1) ATE517097T1 (es)
AU (1) AU2007316681B2 (es)
BR (1) BRPI0718714B8 (es)
CA (1) CA2668399C (es)
CL (1) CL2007003192A1 (es)
ES (1) ES2367455T3 (es)
IL (1) IL198301A (es)
MX (1) MX2009004900A (es)
PE (1) PE20081475A1 (es)
TW (1) TW200829584A (es)
WO (1) WO2008055840A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101152714B1 (ko) 2006-11-09 2012-06-18 에프. 호프만-라 로슈 아게 티아졸 및 옥사졸-치환된 아릴아마이드
US8501933B2 (en) * 2006-11-09 2013-08-06 Roche Palo Alto Llc Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
WO2009058298A1 (en) * 2007-10-31 2009-05-07 Merck & Co., Inc. P2x3, receptor antagonists for treatment of pain
US8461185B2 (en) 2007-10-31 2013-06-11 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
ES2570628T3 (es) * 2007-12-17 2016-05-19 Hoffmann La Roche Nuevas arilamidas con sustitución imidazol
PT2234976E (pt) * 2007-12-17 2013-07-11 Hoffmann La Roche Novas arilamidas substituídas por pirazol
WO2009077371A1 (en) * 2007-12-17 2009-06-25 F. Hoffmann-La Roche Ag Tetrazole-substituted arylamide derivatives and their use as p2x3 and/or p2x2/3 purinergic receptor antagonists
KR101284510B1 (ko) * 2007-12-17 2013-07-23 에프. 호프만-라 로슈 아게 트리아졸 치환된 아릴아미드 유도체 및 ｐ２ｘ３ 및/또는 ｐ２ｘ２／３ 퓨린성 수용체 길항제로서의 용도
JP5539235B2 (ja) * 2008-02-29 2014-07-02 エボテック・アーゲー アミド化合物、組成物およびそれらの使用
EP2346825A2 (en) * 2008-09-18 2011-07-27 Evotec AG Modulators of p2x3 receptor activity
SG172190A1 (en) 2008-12-16 2011-07-28 Hoffmann La Roche Thiadiazole-substituted arylamides
ES2450891T3 (es) 2009-06-22 2014-03-25 F. Hoffmann-La Roche Ag Bifenilamidas útiles como moduladores de receptores P2X3 y/o P2X2/3
WO2010149541A1 (en) * 2009-06-22 2010-12-29 F. Hoffmann-La Roche Ag Novel oxazolone and pyrrolidinone-substituted arylamides
EP2575815A4 (en) * 2010-06-04 2013-12-25 Albany Molecular Res Inc GLYCIN TRANSPORTER 1 INHIBITORS, METHODS OF MAKING THE SAME, AND USES THEREOF
US8698952B2 (en) 2011-10-31 2014-04-15 Lg Innotek Co., Ltd. Camera module
CN105073719B (zh) * 2012-12-07 2017-08-11 拜耳作物科学股份公司 N‑(异噁唑‑3‑基)‑芳基甲酰胺及其用作除草剂的用途
EP2905282A1 (en) 2014-02-05 2015-08-12 AXXAM S.p.A. Substituted thiazole or oxazole as P2X7 receptor antagonists
US10183937B2 (en) 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
DK3587417T3 (da) 2014-12-09 2022-03-28 Bayer Ag 1,3-thiazol-2-yl-substituerede benzamider
KR20160138877A (ko) 2015-05-26 2016-12-06 (주)펠리테크 마이크로파를 이용한 세라믹 발열 하이브리드 건조기
MA46229B1 (fr) 2016-09-15 2020-10-28 Boehringer Ingelheim Int Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
BR112019006216A2 (pt) * 2016-09-30 2019-06-25 Asana Biosciences Llc compostos de p2x3 e/ou p2x2/3 e métodos
WO2020002090A1 (de) 2018-06-25 2020-01-02 Bayer Aktiengesellschaft Substituierte thiazolylpyrrolone sowie deren salze und ihre verwendung als herbizide wirkstoffe
EP3757103A1 (en) * 2019-06-27 2020-12-30 Bayer AG Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases
CN115884970B (zh) * 2020-09-24 2025-09-23 中国医药研究开发中心有限公司 芳基甲酰胺类化合物及其制备方法和医药用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380187B2 (en) 1999-03-25 2002-04-30 Dingwei Tim Yu Class of thiomorpholino substituted thiazoles
DK1194421T3 (da) 1999-06-30 2006-02-13 Lundbeck & Co As H Selektive NPY (Y5) antagonister
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
PL359169A1 (en) 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
EP1539188B1 (en) 2001-01-22 2015-01-07 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
MXPA04004428A (es) * 2001-11-08 2004-09-10 Elan Pharm Inc Derivados de 2,3-diamino-2-hidroxipropano n,n`-sustituidos.
JP2005533777A (ja) 2002-06-17 2005-11-10 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ抗ウイルス剤としての炭素環ヌクレオシドアナログ
WO2004002422A2 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CA2490191C (en) 2002-06-28 2010-08-03 Idenix (Cayman) Limited Modified 2' and 3' -nucleoside prodrugs for treating flaviviridae infections
DK1576138T3 (en) 2002-11-15 2017-05-01 Idenix Pharmaceuticals Llc 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
EP1620089A4 (en) 2003-03-26 2008-12-24 Crc For Asthma Ltd Therapeutic and prophylactic compositions and their uses
AU2004232936B2 (en) 2003-04-18 2008-10-30 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
DE602004005033T2 (de) * 2003-05-12 2007-08-09 Pfizer Products Inc., Groton Benzamidinhibitoren des p2x7-rezeptors
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
EP1658302B1 (en) 2003-07-25 2010-08-25 IDENIX Pharmaceuticals, Inc. Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
ES2391636T3 (es) * 2004-03-05 2012-11-28 F. Hoffmann-La Roche Ag Diaminopirimidinas como antagonistas de P2X3 y P2X2/3
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
EP2592070B1 (en) 2006-06-29 2016-08-31 F. Hoffmann-La Roche AG Tetrazole-substituted arylamides
KR101152714B1 (ko) 2006-11-09 2012-06-18 에프. 호프만-라 로슈 아게 티아졸 및 옥사졸-치환된 아릴아마이드
WO2009058298A1 (en) 2007-10-31 2009-05-07 Merck & Co., Inc. P2x3, receptor antagonists for treatment of pain

Also Published As

Publication number Publication date
AR063601A1 (es) 2009-02-04
BRPI0718714B8 (pt) 2021-05-25
US7786110B2 (en) 2010-08-31
KR101152714B1 (ko) 2012-06-18
US20080132494A1 (en) 2008-06-05
JP5084839B2 (ja) 2012-11-28
ATE517097T1 (de) 2011-08-15
IL198301A (en) 2013-06-27
BRPI0718714A2 (pt) 2013-11-26
TW200829584A (en) 2008-07-16
CN101528717B (zh) 2013-04-24
EP2091927A1 (en) 2009-08-26
KR101165936B1 (ko) 2012-07-19
EP2091927B1 (en) 2011-07-20
CL2007003192A1 (es) 2008-06-20
ES2367455T3 (es) 2011-11-03
BRPI0718714B1 (pt) 2020-09-29
CA2668399C (en) 2015-01-27
KR20090086073A (ko) 2009-08-10
JP2010509264A (ja) 2010-03-25
MX2009004900A (es) 2009-05-19
KR20120034766A (ko) 2012-04-12
CA2668399A1 (en) 2008-05-15
CN101528717A (zh) 2009-09-09
AU2007316681A1 (en) 2008-05-15
AU2007316681B2 (en) 2013-01-24
IL198301A0 (en) 2010-02-17
WO2008055840A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
PE20081475A1 (es) Arilamidas sustituidas por tiazol u oxazol
PE20061357A1 (es) COMPUESTOS DERIVADOS DE AMINOSULFONILO COMO INHIBIDORES DE LA 11-ß-HSD-1
PE20091222A1 (es) Bifenilo sustituidos como moduladores del receptor gpra40
PE20081164A1 (es) Nuevos compuestos 521
AR075051A1 (es) Compuestos antidiabeticos que contienen ftalazina
PE20071009A1 (es) Compuestos derivados de fenoxipiperidinas como antagonistas de histamina h3
PE20081532A1 (es) Compuestos novedosos
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
PE20060693A1 (es) Nuevos derivados de trifluorometansulfonanilida oxamida eter
AR074965A1 (es) Compuestos antidiabeticos heterociclicos puenteados y fusionados
AR063946A1 (es) Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
PE20071156A1 (es) COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA)
GB0517191D0 (en) Compounds
AR058554A1 (es) Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5.
AR063240A1 (es) Derivados de n-aril pirazol,composiciones farmaceuticas que los contienen y usos para el tratamiento de la diabetes tipo2,y enfermedades relacionadas.
PE20060150A1 (es) Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion
AR075049A1 (es) Compuestos antidiabeticos que contienen pentafluorsulfolano
PE20120657A1 (es) Compuesto para el tratamiento de trastornos metabolicos
PE20081577A1 (es) Derivados de sulfonamida ciclicos como inhibidores de la recaptacion de monoamina
AR064318A1 (es) Compuesto y composicion derivada de aril sulfamida, uso del compuesto y proceso para la preparacion del compuesto
PE20081504A1 (es) Compuestos de biciclocarboxiamida sustituidos
PE20140968A1 (es) Derivados de benzamida sustituida
PE20080364A1 (es) Acido bifenilcarboxilicos substituidos y sus derivados como moduladores de la actividad de la gamma-secretasa
BRPI0607600A2 (pt) derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina
AR052938A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor vr1

Legal Events

Date Code Title Description
FD Application declared void or lapsed